In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.
IGBA committed is committed to promoting generic and biosimilar medicines, and exchanging information worldwide. IGBA consists of the following associations:
- Canadian Generic Pharmaceutical Association (CGPA-Canada)
- Medicines for Europe (Europe)
- Association for Accessible Medicines (AAM-USA)
- Japan Generic Medicines Association (JGA-Japan)
- Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
- Generic & Biosimilar Medicines Southern Africa (GBM-Southern Africa)
- Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
- In addition, the generic medicines associations of Australia, Brazil and Mexico are Associate Members
Through its constituent member associations, the IGBA maintains constant dialogue with the ICH, WHO, WTO, WIPO and other international organizations.